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Intestinal resection rates in 
Crohn’s disease decline across 
two different epidemiological 
areas: a consistent observation 
not merely due to introduction 
of anti-TNFα
With great interest we have read the manu-
script written by Murthy et al, published 
in Gut in June 2019, on the influence of 
anti-tumour necrosis factor alpha (TNFα) 
therapy introduction on the rate of hospi-
talisation and intestinal resection rates in 
IBD.1 Despite the difference in the source 
of data between both studies (Canada: 
health administrative data and the Neth-
erlands: nationwide pathology database), 
a declining rate of intestinal resections in 
Crohn’s disease has been confirmed in 
Canada, at equal rates as the decline that 
has been observed in the Netherlands.2
The authors used an advanced statis-
tical method to analyse the impact of anti-
TNFα introduction on (among other end 
points) the rate of intestinal resection. 
However, in our opinion, the hypothesised 
direct relationship between introduction 
of anti-TNFα and a decline in intestinal 
resection rate is vastly oversimplified for 
two important reasons. First, several other 
factors that have influenced both (early) 
diagnosis and management of Crohn’s 
disease should be taken into account. 
Important changes over the past decades 
include improved access to endoscopy, less 
complications at diagnosis and develop-
ment of strict and non-invasive monitoring 
strategies. In their original hypothesis, the 
authors also state the expectation that 
a similar linear decline during the years 
before introduction of infliximab would 
continue during the following years, in 
the absence of infliximab introduction. 
In our opinion, the observed decline 
before introduction of anti-TNFα rather 
confirms that other factors (as mentioned 
above) influence time trends of intestinal 
resection in Crohn’s disease. Second, the 
effect of anti-TNFα introduction on the 
progression of Crohn’s disease should 
preferably be measured on an individual 
patient level during long-term follow-up. 
In this publication, intestinal resection 
rates are only published on an epidemio-
logical and economic level. Data that are 
essential to translate the epidemiological 
trends to clinical practice are the timing of 
anti-TNFα therapy after Crohn’s disease 
diagnosis (ie, possibly only early medical 
intervention will impact the risk of intes-
tinal resection), and the individual risk of 
intestinal re-resection (a marker of long-
term prognosis after a ‘reset’ or ‘new 
onset’ Crohn’s disease after resection).
The conclusion of the authors that 
the use of infliximab in Crohn’s disease 
may be misguided as an explanation for 
the gradually declining rate of intestinal 
resections seems ingrained by the one 
factor-effect hypothesis described above. 
We would rather state more positively 
that among two different epidemiolog-
ical areas, the intestinal resection rate in 
Crohn’s disease is declining, probably as a 
marker of improved prognosis, attributed 
to the improvement of care to patients 
with Crohn’s disease in various ways.
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